This week in Covid news: Global inequities in vaccine doses; travel advice from the C.D.C.; and Cuomo’s book.
A new analysis by The New York Times found that although half a billion doses of the Covid-19 vaccine have been administered worldwide, more than 75% of them have been used by the world’s richest countries. Experts say it is not the poorest countries that are unable to buy the vaccines, but how and when doses were agreed.
In the early days of the pandemic, when drug manufacturers were just beginning to develop vaccines, ordering any of them was a risk. Richer countries could have ordered multiple vaccines, but in doing so have pledged doses that smaller countries may have bought, according to experts.
This has led higher-income countries, such as the United States, to claim doses that, if delivered, could vaccinate the country four times over. Canada has secured several doses that could vaccinate the country six times over the course of this year. But Kenya expects only 30% of its population to be vaccinated by 2023, and this with Covax covers the first 20%.
Covax, a global effort to distribute vaccines evenly managed by the World Health Organization and others, has sought to change the balance. As of March 30, Covax has shipped 32.9 million doses of the vaccine to 70 countries and territories. Most of these missions were donations to low-income countries. To put that number in context, it is only 6% of the 564 million doses administered worldwide.
“Unfortunately, inequalities are on the rise,” said Andrea Taylor, a researcher at Duke University who studies vaccine purchase agreements. flowing from production lines. “
See what else we learned this week:
Federal health officials said Friday that Americans who have been fully vaccinated against Covid-19 can travel at low risk to themselves, but that they must continue to take precautions such as wearing a mask.
As Governor Andrew M. Cuomo of New York wrote a book focusing on his image as a pandemic hero, An imminent Ministry of Health report threatened to reveal a much higher number of coronavirus-related nursing home deaths than previously reported by the Cuomo administration.
A clinical trial of the Pfizer-BioNTech vaccine has been shown to be extremely effective in young adolescents, perhaps even more so than in adults. The study found no symptomatic infections in vaccinated children aged 12 to 15 years, the companies said, and there were no serious side effects. The data have not yet been reviewed by independent experts.